Vall d'Hebron Institute of Oncology (VHIO)
Carlos López Arranz has extensive work experience in business development, innovation management, and knowledge transfer. Carlos began their career at Applus as an EMVCO Level 2 Analysis Operator. Carlos then worked as a Software Developer at Universitat Politècnica de Catalunya. Carlos later joined KIMBCN as a Technologic Consultant, where they focused on project coordination and technology commercialization. Carlos then moved to i2Health Sant Pau as a Project Manager. Following that, they worked at Hospital de la Santa Creu i Sant Pau as a Technology Transfer & Innovation Manager, where they were responsible for commercializing knowledge and technology through licensing agreements and the creation of spin-off companies. Currently, Carlos is working at Vall d'Hebron Institute of Oncology (VHIO) as the Business Development Director, overseeing strategic alliances, licensing, and spin-out creation.
Carlos López Arranz received a Diploma in Telecomunications Engineering from Universitat Politècnica de Catalunya in 2007. Carlos then pursued a Bachelor's degree in Telecomunications Engineering from the same university, which they completed in 2009. In 2008, Carlos also pursued a Master's degree in Telecommunication Engineering & Management (MASTEAM) from Universitat Politècnica de Catalunya. In 2016, they attended Esade for the Program for Management Development (PMD), specializing in Business Administration and Management.
This person is not in any teams
Vall d'Hebron Institute of Oncology (VHIO)
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO) has established itself as a cancer research center of proven excellence internationally. It is thanks to Josep's directorship and VHIO's optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease. Located within the Vall d´Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d´Hebron University Hospital physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients. VHIO's pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread and more effectively treating even the most undruggable tumour types. VHIO's translation toward precision oncology.